1.The role of NAC transcription factors in flower development in plants.
Jiali WANG ; Hebing WANG ; Huiqin YANG ; Ruolin HU ; Dayong WEI ; Qinglin TANG ; Zhimin WANG
Chinese Journal of Biotechnology 2022;38(8):2687-2699
Transcription factors, the proteins with special structures, can bind to specific sites and regulate specific expression of target genes. NAC (NAM, ATAF1/2, CUC1/2) transcription factors, unique to plants, are composed of a conserved N-terminal domain and a highly variable C-terminal transcriptional activation domain. NAC transcription factors are involved in plant growth and development, responses to biotic and abiotic stresses and other processes, playing a regulatory role in flower development. In this paper, we reviewed the studies about NAC transcription factors in terms of discovery, structure, and regulatory roles in anther development, other floral organ development and flowering time. This review will provide a theoretical basis for deciphering the regulatory mechanism and improving the regulatory network of NAC transcription factors in flower development.
Flowers/genetics*
;
Gene Expression Regulation, Plant
;
Phylogeny
;
Plant Proteins/metabolism*
;
Plants/metabolism*
;
Transcription Factors/metabolism*
2. The usage of comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a multicenter, prospective study
Qi WU ; Rong FU ; Mingfeng ZHAO ; Yigai MA ; Hao JIANG ; Liangding HU ; Yu JING ; Hui LIU ; Liru WANG ; Li SU ; Yongqing ZHANG ; Chunlin ZHOU ; Yan ZHANG ; Hanyun REN ; Bin JIANG ; Hebing ZHOU ; Lin KANG ; Lu ZHANG ; Daobin ZHOU ; Jian LI
Chinese Journal of Hematology 2019;40(1):35-39
Objective:
To evaluate the feasibility and potential value of comprehensive geriatric assessment (CGA) in elderly (≥60 years) patients with newly diagnosed acute myeloid leukemia (AML) in China.
Methods:
The CGA results of 83 newly diagnosed AML (non-APL) patients from 16 hospitals in Beijing and Tianjin between March 2016 and December 2017 were prospectively collected and analyzed. The clinical data, treatment and follow-up information were also collected.
Results:
Of 83 newly diagnosed elderly AML patients, 81 patients (97.6%) completed all designated CGA assessment. The median number of impaired scales of the CGA assessment in the studied population was 2(0-6). Sixteen patients (19.3%) showed no impairments according to the geriatric assessment scales implem ented by this study. The distributions of impaired scales were as follows: impairment in ADL, 55.4%; IADL impairment, 42.2%; MNA-SF impairment, 48.2%; cognitive impairment, 15.7%; GDS impairment, 31.7%; HCT-CI impairment, 19.5%, respectively. In patients with "good" ECOG (
3.Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.
Yubo WANG ; Jian MIN ; Xiangping DENG ; Tian FENG ; Hebing HU ; Xinyi GUO ; Yan CHENG ; Baohua XIE ; Yu YANG ; Chun-Chi CHEN ; Rey-Ting GUO ; Chune DONG ; Hai-Bing ZHOU
Acta Pharmaceutica Sinica B 2023;13(12):4963-4982
Endocrine-resistance remains a major challenge in estrogen receptor α positive (ERα+) breast cancer (BC) treatment and constitutively active somatic mutations in ERα are a common mechanism. There is an urgent need to develop novel drugs with new mode of mechanism to fight endocrine-resistance. Given aberrant ERα activity, we herein report the identification of novel covalent selective estrogen receptor degraders (cSERDs) possessing the advantages of both covalent and degradation strategies. A highly potent cSERD 29c was identified with superior anti-proliferative activity than fulvestrant against a panel of ERα+ breast cancer cell lines including mutant ERα. Crystal structure of ERα‒ 29c complex alongside intact mass spectrometry revealed that 29c disrupted ERα protein homeostasis through covalent targeting C530 and strong hydrophobic interaction collied on H11, thus enforcing a unique antagonist conformation and driving the ERα degradation. These significant effects of the cSERD on ERα homeostasis, unlike typical ERα degraders that occur directly via long side chains perturbing the morphology of H12, demonstrating a distinct mechanism of action (MoA). In vivo, 29c showed potent antitumor activity in MCF-7 tumor xenograft models and low toxicity. This proof-of-principle study verifies that novel cSERDs offering new opportunities for the development of innovative therapies for endocrine-resistant BC.